Alkem Laboratories Limited has received a GST demand order from statutory authorities totaling ₹2.18 crores for the period covering 2018-2019 to 2020-2021. The pharmaceutical company disclosed this development under Regulation 30 of SEBI LODR Regulations on January 1st, 2026.

GST Demand Order Details

The order was issued by the Deputy Commissioner, CGST & Central Excise Division – I, Lucknow, and was received by the company on December 31st, 2025. The demand pertains to the company's Uttar Pradesh GSTIN operations during the specified period.

Nature of Alleged Violation

The demand order primarily alleges excess availment of Input Tax Credit under the applicable provisions of the IGST Act, 2017. This relates to the company's GST compliance during the three-year period from 2018 to 2021.

Alkem Laboratories has clearly stated in its disclosure that it does not agree with the demand order and the allegations contained therein.

Company's Response and Next Steps

The company has indicated it is in the process of taking appropriate legal action to contest the order. This includes filing an appeal against the GST demand order through proper legal channels.

According to the company's assessment, there is no material impact expected on its financial, operational, or other activities as a result of this GST order. The disclosure was made in compliance with SEBI regulations to keep stakeholders informed of significant regulatory developments.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulations. The company has also made this information available on its official website at www.alkemlabs.com for public access and transparency.

Alkem Laboratories ' subsidiary Alkem Wellness has successfully completed the sale of its trade generics business through a final payment of ₹32.5 crore, bringing the total transaction value to ₹532.5 crore.

Transaction Overview

The completion of this sale represents a significant milestone in the company's corporate restructuring strategy. The transaction details are summarized below:

Business Divestiture Impact

The sale of the trade generics business marks a strategic shift for Alkem Wellness, allowing the company to focus resources on other core areas. This divestiture is part of the broader pharmaceutical industry trend where companies are streamlining their portfolios to concentrate on specific therapeutic segments.

The completion of the ₹532.5 crore transaction through the final ₹32.5 crore payment indicates that the sale was structured with multiple installments, with this being the concluding payment to finalize the deal.

Corporate Restructuring

This transaction represents one of the significant corporate actions undertaken by the Alkem group, demonstrating the company's strategic approach to portfolio optimization. The successful completion of the sale provides the company with additional financial flexibility while allowing it to exit the trade generics segment.

The finalization of this business sale concludes a major restructuring initiative that will likely influence the company's operational focus and resource allocation in the pharmaceutical sector.